De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients in chronic phase fail to respond to imatinib or to second-generation inhibitors and progress to blast crisis. Until now, improvements in the understanding of the molecular mechanisms responsible for c...

সম্পূর্ণ বিবরণ

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক: Vera Magistroni, Mario Mauri, Deborah D’Aliberti, Caterina Mezzatesta, Ilaria Crespiatico, Miriam Nava, Diletta Fontana, Nitesh Sharma, Wendy Parker, Andreas Schreiber, David Yeung, Alessandra Pirola, Sara Readelli, Luca Massimino, Paul Wang, Praveen Khandelwal, Stefania Citterio, Michela Viltadi, Silvia Bombelli, Roberta Rigolio, Roberto Perego, Jacqueline Boultwood, Alessandro Morotti, Giuseppe Saglio, Dong-Wook Kim, Susan Branford, Carlo Gambacorti-Passerini, Rocco Piazza
বিন্যাস: প্রবন্ধ
ভাষা:English
প্রকাশিত: Ferrata Storti Foundation 2019-09-01
মালা:Haematologica
অনলাইন ব্যবহার করুন:https://haematologica.org/article/view/9045

আন্তর্জাল

https://haematologica.org/article/view/9045

অনুরূপ উপাদানগুলি